Canadian Ticagrelor Survey

Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01757483

Enrollment

244

Registered

2012-12-31

Start date

2012-11-30

Completion date

2014-12-31

Last updated

2015-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Detailed description

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

\- N/A (All prescribers will be contacted for participation)

Exclusion criteria

\- Participation in a previous wave of the survey.

Design outcomes

Primary

Measure	Time frame
KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)	2 months

Secondary

Measure	Time frame
KAU Questionnaire: Practice characteristics	2 months
KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns	2 months
KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.	2 months

Countries

Canada

Outcome results